01.002 RWE KR JULY 2022 G 4-8-22

NICE funding impacts treatment sequencing patterns in chronic myeloid leukaemia (CML)

  • NICE recommendations determine access to tyrosine kinase inhibitors (TKIs)
  • Median duration of treatment by line also decreased as more TKIs were recommended by NICE
  • Promisingly, the study also found that the proportion of patients in major molecular response increased by line
Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at